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Abstract
Enterococcus species are common in nosocomial bloodstream infections and their incidence is rising. Although well recognized in several
serious bacterial infections, the inﬂuence of appropriate antimicrobial therapy in enterococcal bacteraemia has not been fully settled.
The aim of the study was to determine whether administration of inappropriate antibiotics in enterococcal bacteraemia is an indepen-
dent risk factor for mortality, among other known and suspected risk factors. We conducted a cohort study of E. faecalis/faecium bac-
teraemia during a 3-year period at a single tertiary care hospital in Denmark. Patients with growth of non-enterococcus co-pathogens
apart from the enterococcal bacteraemia were also included, as were patients with repeated enterococcal bacteraemia. Time to appro-
priate antimicrobial therapy was counted from the ﬁrst episode. Appropriate antibiotic therapy was deﬁned as any therapy with docu-
mented clinical effect, in vitro activity and a minimum treatment length of 6 days. Multivariate regression models were built to determine
the independent risk factors for mortality. We included 196 patients with enterococcal bacteraemia. Appropriate antibiotics for at least
6 days were administered in 146 of these (74%). Thirty-day mortality was 26%. Multivariate logistic regression identiﬁed independent
predictors of 30-day all-cause mortality: appropriate antimicrobial therapy for ‡6 days (odds ratio for mortality 0.33, 0.14–0.79), ICU
admission (4.2, 1.7–10), thrombocytopenia (3.9, 1.6–9.3), chronic liver failure (3.3, 1.1–10) and age ‡60 years (2.2, 0.99–5.0). Antibiotics
not appropriately covering enterococci are frequently administered empirically in suspected bloodstream infections. Inappropriate
antibiotic therapy was an independent risk factor for mortality in enterococcal bacteraemia.
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Bloodstream infections are major causes of mortality [1]. In
the past decade Enterococcus spp. has become the third most
common aetiological agent isolated in nosocomial blood-
stream infections in the United States [2,3]. In Denmark it
rates fourth [4]. Reported mortality rates after enterococcal
bacteraemia range from 19% to 48% [4–6]. It is generally
accepted that enterococcal bacteraemia often occurs in
patients with underlying illnesses [7] and the observed high
mortality has been ascribed to this issue rather than to the
intrinsic pathogenicity of the Enterococcus spp. Contrary to
this belief, a study including patients with enterococcal bac-
teraemia and matched uninfected controls found a signiﬁcant
excess mortality attributed to Enterococcus spp. of 31% [8].
The rates of infective endocarditis in patients with entero-
coccal bacteraemia vary from 1% to 32% [9,10], thereby only
accounting for a limited part of the mortality in enterococcal
bacteraemia.
Inappropriate and delayed antibiotic therapy has been
reported in several large cohort studies to be associated
with excess mortality [11]. The issue of antimicrobial therapy
in enterococcal bacteraemia is controversial: a few studies
have found no decrease in mortality with appropriate antibi-
otic treatment [12,13]. In contrast, prospective studies have
demonstrated a signiﬁcantly better outcome with appropriate
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antimicrobial therapy, both for vancomycin-resistant (VRE)
and high level gentamicin-resistant (HLGR) Enterococcus spp
[14,15].
The aim of the study was to determine whether adminis-
tration of inappropriate empirical antibiotics in enterococcal
bacteraemia is an independent predictor of mortality, among
other known and suspected risk factors.
Patients and methods
Study design and population
The study was conducted as a retrospective analysis of pro-
spectively collected routine data at Rigshospitalet, Denmark,
a 1120-bed tertiary care and reference facility with approxi-
mately 200 000 patients admitted during the 3-year study for
a total of more than 1 100 000 admission days, and the larg-
est national centre for solid organ transplantation in Den-
mark. All patients at our hospital with a positive blood
culture for E. faecalis and E. faecium between 1 January 2002
and 15 January 2005 were assessed for eligibility. The study
population was identiﬁed in January 2005 using the electronic
log at the Department of Clinical Microbiology at Rigshospi-
talet. (http://www.rh.dk). Patients younger than 16 years and
patients for whom date of death was missing were excluded
from the analyses.
Identiﬁcation and susceptibility testing
Blood cultures were performed using the BD/BACTEC/
9000-system (Becton Dickinson, NJ, USA). Isolates were
identiﬁed using API identiﬁcation (BioMe´rieux, Marcy
I’Etoile, France) and conventional biochemical reactions [16].
Susceptibility testing for E. faecalis and E. faecium was per-
formed using agar diffusion (Statens-Serum-Institut,
Copenhagen, Denmark) with RoscoNeoSensitabs (Rosco
Taastrop, Denmark). Zone diameter breakpoints for antibiot-
ics used refer to the standards listed by the Swedish
Reference Group for Antibiotics (http://www.srga.org) in
combination with those listed by Rosco, Denmark.
In cases with clinically suspected endocarditis, E-test (Bio-
Me´rieux) was performed for penicillin-G and gentamicin.
Notiﬁcation of clinician
When a blood culture was positive for growth the physician
in charge was notiﬁed and advised regarding antimicrobial
chemotherapy and further diagnostic procedures. When
E. faecalis/faecium was identiﬁed including a susceptibility pat-
tern, a follow-up phone call concerning the patient’s progress
and deﬁnitive antimicrobial therapy was performed and a ﬁnal
written report sent to the relevant clinical department.
Data collection
Trained study team members reviewed the medical charts
and extracted demographic data, and information about
hospitalization dates and length, ward, co-morbidities, con-
comitant infections, patients’ discharge diagnoses and clinical
outcomes, including date of death, antibiotic prescription
data, including dosage and number of treatment days of all
administered antimicrobials, indwelling catheters, and vital
status.
Clinical and microbiological data were transferred from
the original chart from the referring hospital to the chart at
our hospital, and these data were recorded whenever possi-
ble into the database. All-cause mortality was registered at
30 days after the onset of bacteraemia in the national central
register, where all deaths and emigrations are registered.
Data concerning clinical characteristics (e.g. concomitant
infections, sepsis, acute liver, and respiratory or renal failure)
and number of positive blood cultures were recorded. The
level of co-morbidity was measured using the Charlson¢s co-
morbidity score [17]. Biochemical data, obtained on the
same day as the blood culture sample, were also collected
and included in the analyses. The suspected source of infec-
tion was recorded from patients’ charts. All data were
entered into the database and marked as ‘not cleared’.
Another member of the study team quality assessed the data
and data were then termed ‘cleared’.
Permission for construction of the database was obtained
from the Danish Data Protection Agency.
Deﬁnitions and criteria
Cultures were regarded as contamination and excluded from
analysis in the absence of (i) a sepsis diagnosis or (ii) signs of
localized infection and clinical data supporting infection [18].
All patients with a non-enterococcus blood stream infec-
tion within ±3 days of the blood culture with Enterococcus
spp. were counted as ‘polymicrobial’. The appropriateness of
the administered antibiotics for use against co-pathogens in
polymicrobial bloodstream infections was assessed as for
therapy against enterococci (see below). Three episodes of
polymicrobial blood stream infection (co-infection with can-
dida spp.) were not included in the mortality analysis because
data on antifungal therapy for these three were incomplete.
Appropriate antimicrobial therapy was deﬁned when: (i)
the antimicrobial therapy was instituted no later than the
day when the blood culture sample was positive for growth
(median 1 day; IQR, 1–2); (ii) the spectrum of the adminis-
tered antibiotics covered the susceptibility of the Enterococ-
cus spp. and was an accepted treatment for enterococcal
infection (see below); (iii) the dosage was adequate according
to national recommendations (Danish national guidelines
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published in the relevant years by a committee of peers from
the Danish Medical Association); dosages could be adjusted
to renal function, weight, etc.; (iv) no contraindications or
relevant interactions with other drugs existed; and (v) anti-
microbials were not discontinued before at least 6 days of
treatment. Patients who died before a full 6-day treatment of
appropriate antimicrobials was given, were maintained in the
group of appropriate antimicrobials for analysis, when antibi-
otics were administered until the date of death.
Antimicrobials regarded as acceptable for enterococcal
bacteraemia were, whenever in vitro: active ampicillin (recom-
mended 2 g three to four times daily), penicillin G (recom-
mended two MIE TID) or piperacillin/tazobactam
(recommended 4 g/0.5 g TID), vancomycin (recommended
1 g BID), linezolid (recommended 600 mg BID) and teicopla-
nin (recommended loading 400 mg BID, followed by 200 mg
BID). Whenever possible (patient tolerance/allergy, resis-
tance, etc.), betalactam therapy was preferred.
The date the positive blood culture was sampled (day 0)
was used to calculate the precise date of death until 30 days
after the onset of bacteraemia.
Statistics
Comparisons between continuous variables were performed
using the Student t-test (normal) or the Mann–Whitney U-
test (non-parametric). Fischer¢s exact-test was used to com-
pare categorical variables.
To determine the independent risk factors for mortality,
the stepwise and best subset approach was used to build a
forward censored logistic regression model with a cut-off of
p <0.1 in the univariate analysis. In the ﬁnal model, the Hos-
mer–Lemeshow assessment of the goodness-of-ﬁt of the
model had a p-value of 0.82. The AUC for the ROC curve
of the identiﬁed predictors was: ICU admittance, 0.68 (95%
CI, 0.59–0.77); platelets <150 · 109/L, 0.66 (0.58–0.75); non-
adequate antimicrobials administered, 0.60 (0.50–0.69); age
>60 years, 0.58 (0.49–0.67); chronic liver insufﬁciency, 0.55
(0.45–0.65). A two-tailed p value £0.05 was considered sta-
tistically signiﬁcant. Analyses of data were performed using
SPSS version 15.0 for Windows (Chicago, IL, USA) and
GraphPad software (San Diego, CA, USA).
A sample size was calculated to detect an odds ratio of
2.2 (Sample Size v. 2.04, CreoStat Software, Fro¨lunda, Swe-
den) [19,20] with a type 1 error risk of 0.05 and a power of
0.8. The frequency of the endpoint in the population, based
on other bacteraemia studies, was set at 0.25, frequency of
risk variable (inappropriate antibiotics) in the population was
set at 0.30, and the multiple correlation of covariates (rho2)
was set at 0.09. Using these estimates, the calculated sample
size was 179 patients.
Results
Bacteraemic episodes
A total of 324 patients with E. faecalis or E. faecium bactera-
emia were evaluated for eligibility. Forty-two patients were
excluded because their age was below 16 years (n = 28) or
they were lost to follow up (n = 14), 79 were excluded due
to incomplete data regarding antibiotic prescription, and
seven patients with central lines were suspected of having
contamination, leaving 196 patients in the study (Fig. 1).
Polymicrobial infections with a clinically signiﬁcant pathogen
occurred in 14% (28/196) of the cases (Staphylococcus aureus
4%, Klebsiella spp. 18%, E. coli 29%, Enterobacter spp. 14%,
Pseudomomas spp. 14% and other spp. 21%). Co-infection
with coagulase-negative staphylococci was present in 14% of
enterococcal bacteraemias.
Baseline characteristics
Appropriate antimicrobial therapy as deﬁned for our study
was administrated in 74% (146/196) of the cases with en-
terococcal bacteraemia. The two groups did not differ con-
cerning age, gender and ICU stay (Table 1). All but one of
the 28 patients with polymicrobial bacteraemia received
appropriate antimicrobials for the secondary pathogen. The
one patient (30-day survivor) not receiving appropriate ther-
apy had a co-infection with clostridium and bacteroides spp.
and received inappropriate therapy for both bacteroides and
enterococcus spp.
Of the nine cases with endocarditis, dual therapy was
administered in seven (betalactam + aminoglycoside in three,
betalactam + vancomycin in two, vancomycin + linezolid in
one, and betalactam + rifampicin + moxiﬂoxacin in one). The




79 incomplete data on antibiotics
14 lost to follow up
28 cases < 16 years








*Enterococcal bacteraemia sampled from intravenous catheter was regarded
as contamination if sepsis was not present 
FIG. 1. Flowchart of study inclusion of cases with enterococcal
bacteremia.
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for the speciﬁc drug and according to possible side-effects,
primarily on renal function.
The median Charlson index [17] of co-morbidity of two
reﬂects a patient population with a high degree of chronic
co-morbidity. However, patients receiving inappropriate anti-
microbial therapy were more often without any co-morbidity
(OR 0.44, 0.21–0.92), and were less represented in the high-
est Charlson score (Table 1).
E. faecalis and E. faecium were evenly distributed. No VRE
strains were identiﬁed in the study.
The majority (78%) of enterococcal blood stream infec-
tions were nosocomially acquired.
Mortality
The mortality rate for enterococcal bacteraemia at 30 days
was 26% (50/196). The administration of appropriate antimi-
crobial therapy was associated with a decreased mortality
(OR 0.39, 0.19–0.78) when compared with patients with
inappropriate antimicrobial therapy (Table 1).
A survival curve for patients receiving appropriate resp.
inappropriate antibiotics is shown in Fig. 2.
The mortality rate for patients with E. faecium bacteraemia
was 36%, compared with 18% for patients with E. faecalis
bacteraemia (OR 2.63, 1.36–5.09). Of the 87 patients with
E. faecalis, the mortality in those who received a beta-lactam
drug for at least 6 days (or until death) was 17.1%, compared
with 19.2% for those who received other classes of drugs
covering enterococci (i.e. glycopeptides or linezolide) for a
similar period of time.
Multivariable regression analysis
The variables included in the regression model analysis for
mortality at 30 days are shown in Table 2. Using forward
censoring with a p-limit of 0.1, seven variables were entered
into the multivariable logistic regression model.
Four independent risk factors were identiﬁed: adminis-
tration of appropriate antibiotics was inversely associated
with death (OR 0.33, 0.14–0.79), ICU admission was a risk
TABLE 1. Baseline and follow-up





(n = 50) p-Value
OR
[95%CI]
Age median/mean (SD) 59/59.5 (12.9) 60/60.3 (13.8) NS
Male gender 89 (61%) 35 (70%) 0.309 0.67 [0.34–1.34]
Age >60 years 64 (44%) 24 (48%) 0.625 0.85 [0.44–1.61]
Mortality 30 (21%) 20 (40%) 0.009 0.39 [0.19–0.78]
Intensive care unit 55 (38%) 21 (42%) 0.617 0.83 [0.43–1.61]
Co-morbidity
Charlson’s index 0 23 (16%) 15 (30%) 0.038 0.44 [0.21–0.92]
Charlson’s index 1 18 (12%) 6 (12%) 1.000 1.03 [0.38–2.76]
Charlson’s index 2 70 (48%) 23 (46%) 0.870 1.08 [0.57–2.06]
Charlson’s index >2 35 (24%) 6 (12%) 0.106 2.31 [0.91–5.88]
Chronic heart failure 27 (18%) 5 (10%) 0.189 2.04 [0.74–5.63]
Chronic lung failure 11 (8%) 6 (12%) 0.383 0.60 [0.21–1.71]
Chronic liver failure 16 (13%) 6 (12%) 0.800 0.90 [0.33–2.45]
Renal failurea 58 (40%) 23 (46%) 0.506 0.77 [0.40–1.48]
Solid tumour cancer 20 (14%) 7 (14%) 1.000 0.95 [0.38–2.41]
Haematological malignancy 42 (29%) 12 (24%) 0.585 1.28 [0.61–2.68]
Organ transplantation 18 (12%) 3 (6%) 0.292 2.20 [0.62–7.83]
Acute presentation
Endocarditis 8 (5%) 2 (4%) 1.000 1.39 [0.29–6.78]
Peritonitis 12 (8%) 14 (28%) 0.001 0.23 [0.10–0.54]
Sepsisb 65 (45%) 28 (56%) 0.190 0.63 [0.33–1.20]
Septic shockb 9 (6%) 5 (10%) 0.353 0.59 [0.19–1.86]
Thrombocytopeniac 84 (58%) 30 (60%) 0.868 0.90 0.47–1.74]
Abdominal source 20 (14%) 16 (32%) 0.006 0.34 [0.16–0.72]
Indwelling catheter source 48 (33%) 10 (20%) 0.106 1.96 [0.90–4.25]
Urinary tract source 19 (13%) 9 (18%) 0.482 0.68 [0.28–1.62]
Respiratory tract source 4 (3%) 4 (8%) 0.117 1.32 [0.08–1.35]
Wound source 5 (3%) 0 (0%) 0.332 3.93 [0.21–72.32]
Skin and soft tissue source 10 (7%) 2 (4%) 0.756 0.85 [0.25–2.83]
Unknown source 39 (27%) 9 (18%) 0.256 1.66 [0.74–3.73]
Microbiological data
Enterococcus faecalis 87 (60%) 26 (52%) 0.408 1.36 [0.71–2.60]
Enterococcus faecium 60 (41%) 23 (46%) 0.620 0.82 [0.43–1.56]
Blood culture obtained
from central catheterd
60 (41%) 15 (30%) 0.180 1.63 [0.82–3.24]
>2 blood culture sets with
Enterococci within ±3 days
37 (25%) 11 (22%) 0.706 1.20 [0.56–2.59]
Polymicrobial infectione 17 (12%) 11 (22%) 0.099 0.47 [0.20–1.08]
aAcute and chronic renal failures were combined.
bDeﬁned by discharge diagnoses.
cA platelet count of <150 · 109/L.
dPatients with blood cultures drawn from central intravenous lines, canalisations of arteries or Hickmann catheters.
eBlood culture with an Enterococcus spp. and another micro-organism (not coagulase-negative staphylococci, propione-
bacteria and corynebacteria). OR, odds ratio, for appropriate antimicrobial therapy.
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factor for death (OR 4.2, 1.7–10), as was thrombocytope-
nia (OR 3.9, 1.6–9.3) and chronic liver failure (OR 3.3,
1.1–10).
Discussion
Beneﬁt of appropriate antibiotic therapy
The study demonstrated that the administration of inappro-
priate antimicrobial therapy to patients with enterococcal
bacteraemia is an independent risk factor for mortality.
Only one study has previously addressed this issue in a
comparably large cohort [14]; however, our study was con-
ducted in a geographical region without VRE strains, thereby
stressing the importance of appropriate antibiotics in serious
enterococcal disease, irrespective of susceptibility pattern
[15]. Despite veriﬁed bloodstream infection with E. faecium
or E. faecalis, 26% of the patients in this study did not receive
appropriate antimicrobial therapy for at least 6 consecutive
days after diagnosis, a rate comparable with the rate found in
other cohort studies of bacteraemia patients [11,21,22]. In
suspected sepsis, antimicrobials active against enterococci are
not always added empirically, a practice questioned by our
results.
Mortality rates and co-morbidity
The high mortality rates for enterococcal bacteraemia (26%)
have been found elsewhere; a recent Danish study [23]
reported an 18% mortality rate from bacteraemia at 30 days
and 25% at 90 days. Vergis et al. [12,13] found a 14-day mor-
tality rate of 19% in 398 cases of enterococcal bacteraemia.
The high co-morbidity rate in our population may in part
explain the high total mortality rates, but not the lower mor-
tality rate observed in patients receiving appropriate antimi-
crobial therapy, thus indicating a substantial effect of
enterococcal infection on the prognosis of the patient. The
appropriate and inappropriate antimicrobial groups were
evenly distributed in the study with regard to co-morbidities
and enterococcal species. An unpublished E. coli bacteraemia
study at Rigshospitalet, conducted by the authors during the
same time period, found similar co-morbidity and mortality
rates (data not shown).
The retrospective design of the study, and the exclusion
of 28% (79/282) of the cases due to incomplete antimicrobial
therapy data, could be considered limitations. While the
sample size does not allow for deﬁnitive conclusions, a rele-
vant sample of patients was included in congruence with the
power calculation.
In conclusion, the use of inappropriate antibiotics in the
ﬁrst 6 days following a case of enterococcal bacteraemia was
an independent risk factor for mortality. In addition to the
clinical implications, these results improve our understanding
of the nature of the enterococcal bloodstream infection. It
would be worthwhile to verify these results in a large,
prospective study.
TABLE 2. Multivariate logistic regression analysis of risk fac-
tors associated with mortality in enterococcal bacteraemia
at 30 days
Variables tested (n = 196)
Multivariate logistic regression
model
p OR [95% CI]
Age and chronic illness variables
Age above 60 years 0.05 2.2 [0.99–5.0]
Chronic lung failure 0.32 1.9 [0.54–6.7]
Chronic liver failure 0.04 3.3 [1.1–10]
Acute illness and complications
Acute respiratory failure 0.68 1.4 [0.47–3.9]
Thrombocytopeniaa 0.002 3.9 [1.6–9.3]
Variables associated with therapy
Appropriate antimicrobial therapy 0.013 0.33 [0.14–0.79]
ICU admission 0.002 4.2 [1.7–10]
Variables with p <0.1 in the univariate analysis were included in the multivariate
model.
aThrombocytopenia was deﬁned as a platelet count of £150 · 109/L.
OR, odds ratio. Hosmer–Lemeshow statistics for goodness of ﬁt, p 0.82. Area
under the receiver operating characteristics curve for the above-found indepen-
dent predictors of 30-day all-cause mortality: ICU-admittance, 0.68 (95% CI,
0.59–0.77); platelets <150 · 109/L, 0.66 (0.58–0.75), non-adequate antimicrobials
administered, 0.60 (0.50–0.69); age >60 years, 0.58 (0.49–0.67); chronic liver
insufﬁciency, 0.55 (0.45–0.65).
Univariate analyses were initially performed for the following variables (apart
from the above): sepsis, peritonitis, endocarditis, renal failure (acute and
chronic), solid tumour cancer, haematological cancer, organ transplantation,
polymicrobial blood stream infection, ‡2 blood culture sets within ±3 days with
enterococci, c-reactive protein ‡50 mg/L, site of infection (suspected clinically/
proven microbiologically): abdominal, indwelling catheter, urinary tract, wound,
skin and soft tissue, lung, other/unknown. Using forward censoring with a p-
value cut-off of 0.1, only the variables displayed in this table were included in
the ﬁnal model. Using a p-value cut-off of 0.2 did result in entering six variables
more in the multivariable model, but the same covariates were identiﬁed as
independent, and with comparable OR as when using 0.1.
FIG. 2. Kaplan-Meier curve survival with and without appropriate
antibiotics.
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